Current Research Opportunities
Leqembi (lecanemab) was granted full FDA approval for the treatment of mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease dementia on July 6, 2023. While this is an exciting step forward in the treatment of Alzheimer’s disease, this medication may not be appropriate for everyone with these diagnoses. If you are interested in finding out if Leqembi (lecanemab) is appropriate for you or your family member, we encourage you to speak with your current Memory Care provider.
If you are interested in finding out more about clinical trial opportunities with the AD-CARE program, contact us at 585-602-5200.
Active studies; open for enrollment:
ADNI4
Federally-funded, ADNI (Alzheimer’s Disease Neuroimaging Initiative) examines historic brain aging through imaging, in the hopes of better understanding how Alzheimer’s Disease functions. This study is observational, seeking people between the ages of 55-90 years old, who have normal cognition, mild cognitive impairment, or dementia.
Alzheimer Prevention Trials (APT) Webstudy
If you are 50 years of age or older, you can monitor your own cognitive health by participating in the Alzheimer Prevention Trials (APT) Webstudy. The APT Webstudy is designed to identify people who may have an increased risk for developing Alzheimer’s disease, using the latest technology to monitor their cognitive performance through regular online memory testing. Volunteers of the APT Webstudy participate at their convenience, anywhere they have access to the internet. APT Webstudy participants benefit by:
- Having their cognitive health assessed over time;
- Being on the ‘fast track’ for relevant clinical trials to prevent Alzheimer’s;
- Making an invaluable contribution to advancing Alzheimer’s research, perhaps helping those in the research field find the first Alzheimer’s survivor; and
- Helping ensure that future generations do not experience Alzheimer’s and its difficult challenges.
To participate in the APT Webstudy or to learn more, please visit www.aptwebstudy.org
Synaptic Therapy Alzheimer's Research Trial (START)
A phase 2, double-blind, placebo-controlled study funded by the National Institute of Health and National Institute on Aging to evaluate the safety and efficacy of CT1812 in early Alzheimer's disease.
___________________________________________________________
Studies Coming Soon:
Trailrunner
______________________________________________________________
Active studies; not open for enrollment:
AHEAD A3-45
The AHEAD A3-45 study is funded by the National Institute on Aging (NIA) in partnership with the Alzheimer’s Clinical Trial Consortium (ACTC), Eisai Co., and collaboration with Biogen Inc. The AHEAD study will test if the investigational treatment, BAN2401, could lower brain amyloid levels and/or prevent cognitive decline in people with amyloid buildup in the brain, in individuals who do not have a diagnosis of a memory disease. For more information, please visit the website: https://www.aheadstudy.org/
ALZ-801
Sponsored by Alzheon Inc, this Phase 3 study will investigate the efficacy and tolerability of an investigation drug (ALZ-801) in participants with early AD and who are APOE4/4 carriers.
Clarity AD
Sponsored by Eisai Inc., in collaboration with Biogen Inc., this study assesses safety, tolerability, and efficacy of an experimental medication (BAN2401) in people with early Alzheimer’s disease.
https://clinicaltrials.gov/ct2/show/NCT03887455
LIFT-AD
Sponsored by Athira Pharma with funding from the Alzheimer’s Association, this study evaluates the safety and efficacy of an investigation drug (ATH-1017) for the treatment of individuals with mild to moderate Alzheimer's disease. To learn more on about the investigational drug, click here. For more information about the study, please visit: https://classic.clinicaltrials.gov/ct2/show/NCT04488419
RETHINK-ALZ
Sponsored by Cassava Sciences, the goal of the study is to investigate the safety and efficacy of simufilam (PT-125) in enhancing cognition and slowing cognitive and functional decline in people with mild to moderate Alzheimer's disease.
clinicaltrials.gov/ct2/show/NCT04994483.
TRAILBLAZER-ALZ 2
Sponsored by the Eli Lilly and Company, this study will evaluate the safety and efficacy of the investigational study drug (donanemab) in participants with early Alzheimer’s disease.
https://trailblazer2study.com/
_____________________________________________![]()
For more information on additional study opportunities, please visit: https://www.alz.org/research/clinical_trials/find_clinical_trials_trialmatch.asp